Objectives: To describe oral contraceptive (OC) use, its determinants and use-associated health correlates from 1984 to 1999 in Germany.
Study Design: Cross-sectional comparison was performed for socioeconomic factors, personal lifestyle and use-associated health correlates between 1862 OC users and 2625 age-matched nonusers identified from five German National Health Surveys. Regression models were used to obtain the determinants of OC use.
Results: While in women aged 25-49 years OC use remained nearly constant in the western part of Germany from 1984 to 1999 (17.3-20.1%), it declined greatly in the eastern part from 43.0% in 1991 to 32.3% in 1999. Cross-sectional comparison and regression analysis suggested that OC users did not differ from nonusers in most selected personal and socioeconomic factors. OC users showed generally a better health profile than age-matched nonusers with more satisfaction with health, higher quality of life and no significant difference in history of cardiovascular diseases despite slightly higher prevalence of hypertension and hyperlipidemia that are of little clinical significance.
Conclusions: OC use seems to be generally safe. Whether the better health profiles found in OC users are the results of OC use or effects of healthy users, or both, should be further studied.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejogrb.2007.01.007 | DOI Listing |
Am J Obstet Gynecol
January 2025
Department of Obstetrics and Gynecology, University Hospitals Cleveland Medical Center, Cleveland OH; Department of Reproductive Biology, Case Western Reserve University, Cleveland, OH. Electronic address:
Background: The use of glucagon-like-peptide-1 receptor agonists (GLP-1RAs) has greatly increased in patients of reproductive age within the past four years. However, there is minimal research into the long-term impact of these medications on future pregnancies.
Objectives: We aimed to evaluate the association between adverse obstetric outcomes and antecedent GLP-1RA use using a nationally representative database.
Metab Brain Dis
January 2025
Florey Institute of Neuroscience & Mental Health, Parkville, VIC, Australia.
Substance use disorders (SUDs) pose a significant global health challenge, with relapse being a major obstacle in achieving successful treatment outcomes. In recent years, drug delivery strategies have emerged as promising tools to improve treatment efficacy and patient compliance in the context of SUD. Here we explore a diverse range of drug delivery strategies that have been investigated for addressing relapse behavior in SUD.
View Article and Find Full Text PDFBMJ Open
December 2024
Institute for Cardio-Metabolic Medicine, University Hospital Coventry & Warwickshire NHS Trust, University of Warwick Medical School and Coventry University, Coventry, UK
Objective: To estimate the resource use of patients with obstructive hypertrophic cardiomyopathy (HCM), stratified by New York Heart Association (NYHA) class, in the English and Northern Irish healthcare systems via expert elicitation.
Design: Modified Delphi framework methodology.
Setting: UK HCM secondary care centres (n=24).
Eur Clin Respir J
January 2025
Department of Cardiothoracic Anesthesia and Intensive Care, The Heart Centre, University Hospital of Copenhagen, Denmark.
E-cigarette or vaping product use-associated lung injury (EVALI) is a potentially severe acute interstitial lung disease primarily observed in the United States, with sporadic cases reported in Europe. EVALI, though rare, could be susceptible to under-diagnosis due to limited awareness and diagnostic suspicion. We present a case of a 19-year-old male in Denmark diagnosed with severe EVALI.
View Article and Find Full Text PDFDrug Alcohol Depend
February 2025
Center for Tobacco Control Research and Education, University of California San Francisco, 95 Kirkham Street Box 1361, San Francisco, CA 94143, United States.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!